CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.

Why Google, Apple, and Amazon entering the diabetes market is the real big story from ADA.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

A 78-year old patient with a 15-year history of type 2 diabetes arrives in your office for a check-up. He suffers from stage 3 chronic kidney disease and lives alone. From previous visits you have learned he has very few support services. What would be a realistic A1C treatment target for this individual? A. A1C 6.0-6.5% B. A1C 7.5-8.0% C. A1C 8.5-10.0% D. A1C 10.5-11% Follow the link to see the correct answer!

Would you consider using a combination of SGLT-2 Inhibitor along with an GLP-1 Agonist, now or in the future? Follow the link to see how you and your colleagues compare!

MedAngel ONE is the best solution to monitor and protect temperature sensitive medications like insulin. Continuous monitoring and logging ensures that you and your patients can always can always see beyond doubt if your medications were stored properly. It supports hundreds of FDA approved medications and adapts the smart alerts to them. If a dangerous temperature is approached or exceeded, the app will alert you immediately. Read on for details and for a special discount + Free shipping Use code: Med10.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 1 of this …